Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Motolimod (VTX-378) 是一种有效且特异性的 Toll 样受体 8 (TLR8) 激动剂,EC50约为 100 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 519 | 现货 | ||
2 mg | ¥ 758 | 现货 | ||
5 mg | ¥ 1,230 | 现货 | ||
10 mg | ¥ 1,970 | 现货 | ||
25 mg | ¥ 3,670 | 现货 | ||
50 mg | ¥ 5,290 | 现货 | ||
100 mg | ¥ 7,270 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,250 | 现货 |
产品描述 | Motolimod (VTX-378) (VTX-2337) is an effective and specific Toll-like receptor (TLR) 8 agonist (EC50: 100 nM), > 50-fold selectivity over TLR7. |
靶点活性 | TLR8:100 nM(EC50) |
体外活性 | VTX-2337 induces the production of both TNFα (EC50: 140 nM) and IL-12 (EC50: 120 nM) in PBMCs. In mDCs and monocytes, VTX-2337 specifically induces the production of IL-12 and TNFα via NF-κB activation. VTX-2337 also induces IFNγ production from NK cells, enhances the lytic function of NK cells and augments ADCC. |
体内活性 | In ovarian cancer mouse model, TX-2337 augments the effect of pegylated liposomal doxorubicin (PLD). |
激酶实验 | The activity of specific TLR agonists is assessed using the secretory embryonic alkaline phosphatase (SEAP) reporter gene that is linked to NF-κB activation in response to TLR stimulation. Measurement of SEAP activity using the Quanti-blue substrate (InvivoGen) after TLR agonist treatment is carried out. |
细胞实验 | PBMCs or purified NK cells are prepared as previously described, and the purity of NK cells was approximately 99%. NK cell-mediated cytotoxicity is assessed by Calcein-AM release from labeled target cells. In brief, PBMCs or purified NK cells are cultured for 48 hours in RPMI medium in the presence of VTX-2337 (167 or 500 nmol/L) before incubation with target cells. |
别名 | VTX-378, VTX-2337 |
分子量 | 458.6 |
分子式 | C28H34N4O2 |
CAS No. | 926927-61-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 12 mg/mL (26.2 mM)
DMSO: 51 mg/mL (111.2 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.1805 mL | 10.9027 mL | 21.8055 mL | 54.5137 mL |
5 mM | 0.4361 mL | 2.1805 mL | 4.3611 mL | 10.9027 mL | |
10 mM | 0.2181 mL | 1.0903 mL | 2.1805 mL | 5.4514 mL | |
20 mM | 0.109 mL | 0.5451 mL | 1.0903 mL | 2.7257 mL | |
DMSO | 50 mM | 0.0436 mL | 0.2181 mL | 0.4361 mL | 1.0903 mL |
100 mM | 0.0218 mL | 0.109 mL | 0.2181 mL | 0.5451 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Motolimod 926927-61-9 Immunology/Inflammation TLR inhibit VTX-378 VTX378 VTX 2337 VTX2337 Inhibitor Toll-like Receptor (TLR) VTX-2337 VTX 378 inhibitor